Tatva Chintan Pharma Chem Limited (NSE:TATVA)
India · Delayed Price · Currency is INR 1,115.10
-51.90 (-4.45%)
Aug 1, 2025, 3:29 PM IST
Bally's Revenue
Tatva Chintan Pharma Chem had revenue of 1.17B INR in the quarter ending June 30, 2025, with 10.81% growth. This brings the company's revenue in the last twelve months to 3.94B, up 2.47% year-over-year. In the fiscal year ending March 31, 2025, Tatva Chintan Pharma Chem had annual revenue of 3.83B, down -2.74%.
Revenue (ttm)
3.94B
Revenue Growth
+2.47%
P/S Ratio
6.62
Revenue / Employee
5.72M
Employees
689
Market Cap
26.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.83B | -107.90M | -2.74% |
| Mar 31, 2024 | 3.94B | -301.08M | -7.11% |
| Mar 31, 2023 | 4.24B | -100.35M | -2.31% |
| Mar 31, 2022 | 4.34B | 1.33B | 44.38% |
| Mar 31, 2021 | 3.00B | 371.20M | 14.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UltraTech Cement | 784.12B |
| Asian Paints | 338.41B |
| Grasim Industries | 1,484.78B |
| Vedanta | 1,535.31B |
| Pidilite Industries | 131.40B |
| Solar Industries India | 75.40B |
| Shree Cement | 192.83B |
| Jindal Steel | 497.65B |